Mereo BioPharma (LSE) ((GB:MPH)), Mereo Biopharma ((MREO)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mereo BioPharma, in collaboration with Ultragenyx Pharmaceutical Inc, is conducting a pivotal study titled ‘Setrusumab vs Placebo for Osteogenesis Imperfecta.’ The study aims to determine an effective dosing strategy for setrusumab and assess its impact on reducing fracture rates in patients with Osteogenesis Imperfecta (OI), a genetic disorder characterized by fragile bones. This study is significant as it could lead to a new treatment option for OI, potentially improving quality of life for affected individuals.
The intervention being tested is setrusumab, a fully human sclerostin neutralizing monoclonal antibody. It is administered monthly via intravenous infusion and is designed to strengthen bone by inhibiting sclerostin, a protein that negatively regulates bone formation.
The study is interventional, with a randomized, sequential design. It involves a single-blind Phase 2 dose-evaluation phase followed by a double-blind, placebo-controlled Phase 3. The primary purpose is treatment, with quadruple masking to ensure unbiased results.
The study began on February 21, 2022, and is currently active but not recruiting. The last update was submitted on August 5, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.
This update could influence Mereo BioPharma’s stock performance positively if the results show efficacy, as it would enhance their product pipeline. Investor sentiment might also improve, given the potential for a new treatment in a niche market. Competitors in the bone disease treatment sector will be closely monitoring these developments.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.